Monthly assessment of circulating CD5+/CD19+ and CD19+/B220dim leukemia cells in all treated mice displayed a lower leukemic burden at 6 and 12 months, contributing to considerable survival prolongation in mice receiving ibrutinib at 12 months of age (Fig. 6A, B). This evidence concerns the gene CD5 and leukemia.